Exploring the Trypanosoma brucei Hsp83 Potential as a Target for Structure Guided Drug Design

PLoS Neglected Tropical Diseases

Volumn 7, Issue 10, 2013, Pages

  Pizarro, Juan Carlos ^a,b   Hills, Tanya ^a   Senisterra, Guillermo ^a   Wernimont, Amy K ^a   Mackenzie, Claire ^c   Norcross, Neil R ^c   Ferguson, Michael A J ^c   Wyatt, Paul G ^c   Gilbert, Ian H ^c   Hui, Raymond ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TULANE UNIVERSITY   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 [2,4 DICHLORO 5 (2 DIETHYLAMINOETHOXY)PHENYL]THIOPHENO[2,3 D]PYRIMIDINE 6 CARBOXYLIC ACID ETHYLAMIDE; 4 [6,6 DIMETHYL 4 OXO 3 (TRIFLUOROMETHYL) 4,5,6,7 TETRAHYDRO 1H INDAZOL 1 YL] 2 [(2 (METHYLTHIO)ETHYL)AMINO]BENZAMIDE; 4 [6,6 DIMETHYL 4 OXO 3 (TRIFLUOROMETHYL) 4,5,6,7 TETRAHYDRO 1H INDAZOL 1 YL] 2 [(TRANS 4 HYDROXYCYCLOHEXYL)AMINO]BENZAMIDE; 6 CHLORO 9 (4 METHOXY 3, DIMETHYLPYRIDIN 2 YLMETHYL) 9H PURIN 2 YLAMINE; 9 (SEC BUTYL) 8 (2,5 DIMETHOXYBENZYL) 2 METHYL 9H PURIN 6 AMINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 83; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; N4 [8 (5 ACETYLPYRIDIN 2 YL) 8 AZABICYCLO[3 2 1]OCT 3 ENDO YL] 2 [(TRANS 4 HYDROXYCYCLOHEXYL)AMINO]BENZENE 1,4 DICARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLIZATION; DIFFERENTIAL SCANNING FLUORIMETRY; DRUG DESIGN; ENZYMATIC ASSAY; GEL PERMEATION CHROMATOGRAPHY; GROWTH INHIBITION; ISOTHERMAL TITRATION CALORIMETRY; MASS SPECTROMETRY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TRYPANOSOMA BRUCEI; TRYPANOSOMIASIS; X RAY CRYSTALLOGRAPHY;

ANTIPROTOZOAL AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PARASITIC SENSITIVITY TESTS; PROTEIN BINDING; PROTOZOAN PROTEINS; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84887275447     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002492     Document Type: Article

References (64)

1. Malvy D, Chappuis F, (2011) Sleeping sickness. Clin Microbiol Infect 17: 986-995.
2. Barrett MP, Boykin DW, Brun R, Tidwell RR, (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152: 1155-1171.
3. Burri C, (2010) Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 137: 1987-1994.
4. Brun R, Don R, Jacobs RT, Wang MZ, Barrett MP, (2011) Development of novel drugs for human African trypanosomiasis. Future Microbiol 6: 677-691.
5. Neckers L, (2007) Heat shock protein 90: the cancer chaperone. J Biosci 32: 517-530.
6. Meyer KJ, Shapiro TA, (2013) Potent Anti-trypanosomal Activities of Hsp90 Inhibitors in Vitro and in Vivo. J Infect Dis 208 (3) (): 489-99.
7. Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, et al. (2010) Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 285: 37964-37975.
8. Devaney E, O'Neill K, Harnett W, Whitesell L, Kinnaird JH, (2005) Hsp90 is essential in the filarial nematode Brugia pahangi. Int J Parasitol 35: 627-636.
9. Wiesgigl M, Clos J, (2001) The heat shock protein 90 of Leishmania donovani. Med Microbiol Immunol 190: 27-31.
10. Shahinas D, Liang M, Datti A, Pillai DR, (2010) A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 53: 3552-3557.
11. Taipale M, Jarosz DF, Lindquist S, (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528.
12. Hartl FU, Bracher A, Hayer-Hartl M, (2011) Molecular chaperones in protein folding and proteostasis. Nature 475: 324-332.
13. Tsutsumi S, Beebe K, Neckers L, (2009) Impact of heat-shock protein 90 on cancer metastasis. Future Oncol 5: 679-688.
14. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
15. Koga F, Kihara K, Neckers L, (2009) Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 29: 797-807.
16. Porter JR, Fritz CC, Depew KM, (2010) Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14: 412-420.
17. Krukenberg KA, Street TO, Lavery LA, Agard DA, (2011) Conformational dynamics of the molecular chaperone Hsp90. Q Rev Biophys 44: 229-255.
18. Banumathy G, Singh V, Pavithra SR, Tatu U, (2003) Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem 278: 18336-18345.
19. Van der Ploeg LH, Giannini SH, Cantor CR, (1985) Heat shock genes: regulatory role for differentiation in parasitic protozoa. Science 228: 1443-1446.
20. Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, et al. (2010) TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res 38: D457-462.
21. Vedadi M, Lew J, Artz J, Amani M, Zhao Y, et al. (2007) Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol Biochem Parasitol 151: 100-110.
22. Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, et al. (2007) Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 50: 2767-2778.
23. Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, et al. (2006) Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem 49: 817-828.
24. Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, et al. (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 52: 4794-4809.
25. Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, et al. (2009) Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52: 4288-4305.
26. Bussenius J, Blazey CM, Aay N, Anand NK, Arcalas A, et al. (2012) Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett 22: 5396-5404.
27. McCoy AJ, (2007) Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr D Biol Crystallogr 63: 32-41.
28. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
29. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
30. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501.
31. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67: 355-367.
32. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235-242.
33. Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, et al. (2011) Buster. 2.8.0 ed. Cambridge, U.K.: Global Phasing.
34. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
35. Chen VB, Arendall WB, (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12-21.
36. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
37. Kabsch W, Kabsch H, Eisenberg D, (1976) Packing in a new crystalline form of glutamine synthetase from Escherichia coli. J Mol Biol 100: 283-291.
38. Laskowski RA, Swindells MB, (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51: 2778-2786.
39. Brand S, Cleghorn LA, McElroy SP, Robinson DA, Smith VC, et al. (2012) Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 55: 140-152.
40. McLaughlin SH, Smith HW, Jackson SE, (2002) Stimulation of the weak ATPase activity of human hsp90 by a client protein. J Mol Biol 315: 787-798.
41. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, et al. (2004) High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 327: 176-183.
42. Onuoha SC, Mukund SR, Coulstock ET, Sengerova B, Shaw J, et al. (2007) Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 372: 287-297.
43. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, et al. (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Research 68: 2850-2860.
44. Leskovar A, Wegele H, Werbeck ND, Buchner J, Reinstein J, (2008) The ATPase cycle of the mitochondrial Hsp90 analog Trap1. J Biol Chem 283: 11677-11688.
45. Martin CJ, Gaisser S, Challis IR, Carletti I, Wilkinson B, et al. (2008) Molecular characterization of macbecin as an Hsp90 inhibitor. J Med Chem 51: 2853-2857.
46. Prodromou C, Nuttall JM, Millson SH, Roe SM, Sim TS, et al. (2009) Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem Biol 4: 289-297.
47. Zurawska A, Urbanski J, Matuliene J, Baraniak J, Klejman MP, et al. (2010) Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. Biochim Biophys Acta 1803: 575-583.
48. Fadden P, Huang KH, Veal JM, Steed PM, Barabasz AF, et al. (2010) Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol 17: 686-694.
49. Citri A, Kochupurakkal BS, Yarden Y, (2004) The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3: 51-60.
50. Cowen LE, (2009) Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog 5: e1000471.
51. Cowen LE, Lindquist S, (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
52. Li Q, Zhou Y, Yao C, Ma X, Wang L, et al. (2009) Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage. Parasitol Res 105: 1539-1548.
53. Kumar R, Musiyenko A, Barik S, (2005) Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol 141: 29-37.
54. Fedorov O, Niesen FH, Knapp S, (2012) Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol Biol 795: 109-118.
55. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
56. Waldron TT, Murphy KP, (2003) Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics. Biochemistry 42: 5058-5064.
57. Matulis D, Kranz JK, Salemme FR, Todd MJ, (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44: 5258-5266.
58. Holdgate GA, Ward WH, (2005) Measurements of binding thermodynamics in drug discovery. Drug Discov Today 10: 1543-1550.
59. Niesen FH, Berglund H, Vedadi M, (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2: 2212-2221.
60. Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, et al. (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 11: 775-785.
61. Barluenga S, Fontaine JG, Wang C, Aouadi K, Chen R, et al. (2009) Inhibition of HSP90 with pochoximes: SAR and structure-based insights. Chembiochem 10: 2753-2759.
62. Roughley S, Wright L, Brough P, Massey A, Hubbard RE, (2011) Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening. Top Curr Chem 317: 61-82.
63. Park SJ, Kostic M, Dyson HJ, (2011) Dynamic Interaction of Hsp90 with Its Client Protein p53. J Mol Biol 411: 158-173.
64. Armstrong H, Wolmarans A, Mercier R, Mai B, LaPointe P, (2012) The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922. PLoS One 7: e49322.